Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma
Overview
- Phase
- Not Applicable
- Intervention
- Urinary sample
- Conditions
- Clear Cell Renal Cell Carcinoma
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Number of patients (with clear cell kidney cancer) with CD9+ and CA9+ exosomes by electron microscopy technique
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Clear cell renal cell carcinoma is diagnosed by imaging, sometimes associated with biopsy. This diagnosis is expensive, invasive and sometimes late. The development of a simple biological test for diagnosis is essential. Exosomes are 30 to 150 nm membrane vesicles secreted into the extracellular space by various living cells. These exosomes can be isolated from biological fluids, including urine. The recent study of urinary exosomes is a promising topic for analyzing tumor markers in urine. The investigator's goal is to develop a reliable technique for detecting tumor exosomes in urine in patients with clear cell renal cell carcinoma. The analysis of urinary exosomes could provide a new liquid biopsy tool for the early diagnosis of clear cell renal cell carcinoma.
Detailed Description
The primary objective is to detect urinary exosomes, by electron microscopy technique, from clear cell renal cell carcinoma due to exosome markers (CD9) and clear cell kidney cancer (CA9).
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients with renal mass requiring surgery (partial or total nephrectomy)
- •Social security affiliation
- •Signed informed consent
- •Unscheduled nephrectomy
- •Social security affiliation
- •Signed informed consent
Exclusion Criteria
- •Insufficient volume of urine sample (\< 100 ml)
- •Patients with a urinary catheter
- •Patients under court-ordered guardianship or curators
Arms & Interventions
Renal mass patients
Patients with renal mass requiring surgery (partial or total nephrectomy) will be included. They will have an urinary sample.
Intervention: Urinary sample
Control patients
Control patients (without renal mass) will be included. They will have an urinary sample.
Intervention: Urinary sample
Outcomes
Primary Outcomes
Number of patients (with clear cell kidney cancer) with CD9+ and CA9+ exosomes by electron microscopy technique
Time Frame: At inclusion
Measured by analysis in electron microscopy technique of urinary sample.
Secondary Outcomes
- Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for control patients(At inclusion)
- Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients(At inclusion)
- Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients(At inclusion)
- Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for control patients(Years: 2)
- Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+/VGEFR2+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+ /CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by electron microscopy technique (%) for control patients(At inclusion)
- Percentage of CD9+ /CA9+ exosomes by electron microscopy technique (%) for patients with clear cell kidney cancer(At inclusion)
- Percentage of CD9+ /CA9+ exosomes by flow cytometry (%) for control patients(At inclusion)
- Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by flow cytometry (%) for control patients(At inclusion)
- Percentage of CD9+/CD63+/CD81+/CA9+ exosomes by Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) (%) for patients with clear cell kidney cancer(Years: 2)
- Percentage of CD9+/VGEFR2+ exosomes by electron microscopy technique (%) for control patients(At inclusion)
- Percentage of CD9+/VGEFR2+ exosomes by flow cytometry (%) for control patients(At inclusion)